Leerink lifts Gilead price target to $146, citing Yeztugo uptake and HIV pipeline strength
Leerink Partners raised its price target on Gilead Sciences to $146 from $114 while keeping an Outperform rating, pointing to strong early commercial adoption of Yeztugo (lenacapavir for PrEP) and a bolstered HIV pipeline. The firm expects positive commentary at Gilead's upcoming fourth-quarter 2025 results and highlighted 2026 regulatory milestone…